News

TOKYO, January 24, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the financial forecast for fiscal year 2024 announced on October 30, 2024 (Core basis and Full basis), has been revised in accordance with progress in core business and booking impairment loss as follows. Progress in Core Business: Mainly, the expansion of sales of XTANDI™...

TOKYO, January 9, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) accepted the revised supplemental New Drug Application (sNDA) for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on January 6, 2025...

- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years 1 - NMPA approval based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the treatment combination significantly improved overall survival and progression-free...

- China has the highest number of cases and deaths from gastric cancer of any country worldwide 1 - - Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed by 35% of Chinese patients with advanced gastric and gastroesophageal junction (GEJ) cancer 2 - - Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend...

- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales -...